Amendment No. 1 to Business Combination Agreement, dated September 6, 2022, among Deep Medicine Acquisition Corp., Chijet Inc., Chijet Motor Company, Inc., Chijet Motor (USA) Company, Inc. and the Sellers named therein (holding in excess of 50% of Chijets outstanding shares)

Exhibit 2.1

Amendment No. 1

To

BUSINESS COMBINATION AGREEMENT

This Amendment No. 1 to Business Combination Agreement (this “Amendment”) is made and entered into as of September 6, 2022 (the “Amendment Date”) by and among (i) Deep Medicine Acquisition Corp., a Delaware corporation (“DMAC”), (ii) Chijet Motor Company, Inc., a Cayman Islands exempted company and a wholly owned subsidiary of the Company (as defined below) (“Pubco”), (iii) Chijet Motor (USA) Company, Inc., a Delaware corporation and a wholly owned subsidiary of Pubco (“Merger Sub”), (iv) Chijet Inc., a Cayman Islands exempted company (the “Company”), and (v) Sellers (as defined the Original Agreement (as defined below)) holding in the aggregate a Pro Rata Share (as defined in the Original Agreement) in excess of fifty percent (50%). DMAC, Pubco, Merger Sub, the Company and the Sellers signatory hereto are sometimes referred to herein individually as a “Party” and, collectively, as the “Parties”.

WHEREAS, the Parties are all parties to that certain Business Combination Agreement, dated as of July 12, 2022 (the “Original Agreement”) and now desire to amend the Original Agreement as set forth herein;

WHEREAS, pursuant to the provisions of Section 13.8 of the Original Agreement, the Original Agreement may be amended in writing signed by DMAC, Pubco, the Company and Sellers holding in the aggregate a Pro Rata Share in excess of fifty percent (50%);

NOW, THEREFORE, in consideration of the premises set forth above, which are incorporated in this Agreement as if fully set forth below, and the representations, warranties, covenants and agreements contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledges and agreed, and intending to be legally bound hereby, the Parties hereby agree as follows:

Following the Effective Date and during the period commencing on the Effective Date and ending on September 20, 2022 (the “Due Diligence Period”), DMAC and its Representatives shall (i) undertake a due diligence review of the Company Entities and their operations; and (ii) complete DMAC’s own determination of the Valuation (the “Revised Valuation”). DMAC shall notify the Company of the Revised Valuation at or prior to the end of the Due Diligence Period.

[Signatures appear on following pages]

IN WITNESS WHEREOF, each Party hereto has caused this Amendment to be signed and delivered by its respective duly authorized officer as of the Amendment Date.